Related Experiment Video
Updated: May 17, 2026
04:03
Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
Published on: September 27, 2024
Aclidinium: in chronic obstructive pulmonary disease.
1Adis, Auckland, New Zealand. demail@springer.co.nz
Drugs
|October 11, 2012
Summary
Aclidinium, an inhaled long-acting antimuscarinic agent, effectively improved lung function and COPD symptoms in patients with moderate to severe disease. The treatment demonstrated a favorable safety profile over 52 weeks.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Chronic obstructive pulmonary disease (COPD) requires effective long-term maintenance treatments.
- Long-acting antimuscarinic agents are a key therapeutic class for COPD management.
Purpose of the Study:
- To evaluate the efficacy and safety of aclidinium, an inhaled long-acting antimuscarinic agent, as a twice-daily maintenance treatment for COPD.
- To assess aclidinium's impact on bronchodilation, health status, dyspnea, and exacerbations in patients with moderate to severe COPD.
Main Methods:
- Two pivotal trials (ACCORD COPD I and ATTAIN) involving patients with moderate to severe COPD.
- Patients received aclidinium (400 μg twice daily) or placebo for 12 or 24 weeks.
Main Results:
- Aclidinium significantly improved bronchodilation, disease-specific health status, dyspnea, and reduced rescue medication use compared to placebo.
- Clinically meaningful improvements were observed after 24 weeks, with similar trends at 12 weeks.
- Aclidinium showed a statistically significant reduction in COPD exacerbations, though not powered for this outcome.
Conclusions:
- Twice-daily aclidinium is an effective maintenance treatment for moderate to severe COPD, improving key clinical endpoints.
- Aclidinium was well-tolerated in clinical trials up to 52 weeks, with a safety profile similar to placebo.
- The inhaled agent demonstrated low systemic bioavailability and a low incidence of cardiovascular and anticholinergic adverse events.
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.